Emergency Department Use in Patients with Cancer: A Population-Based Study

Introduction Emergency Department (ED) visits in cancer patients represent a significant burden to both patients and the health care system. Emergency Care of cancer patients is complex compared to the population. There is lack of knowledge regarding the pattern and reasons for ED visits in this population. Objectives and Approach We sought to identify factors and patterns associated with ED use among cancer patients, in the first year after diagnosis. Adult cancer patients diagnosed between 2011 and 2013 were identified from the Alberta Cancer Registry. This was linked with cancer related treatments extracted from medical records system at provincial cancer centers. ED visits and outpatient clinics were acquired from National Ambulatory Care Reporting System (NACRS). Databases were linked by unique patient identification number. Previous cancer patients were defined by having at least one cancer related diagnosis in NACRS before. The other patients were treated as non-cancer patients. Results Cancer patients accounted for 6.7% of ED visits and 10\% of ED hours. They had higher male percentage (53% vs. 49%), higher admission rate (23% vs. 10%), ambulance usage (20% vs. 12%) and longer stay (LOS) (171 vs. 131 mins) compared to non-cancer patients. 24% of cancer patients had 4 or more ED visits/year and accounted for 59% of visits. Lung and liver cancer patients had higher ED utilization than patients with other cancers. Breast cancer patients had more after-treatment-ED-visits (41% within a week vs. 26% in lung cancer). Use of ED was highest within 1 month of diagnosis for all types except breast cancer, which was highest at 2 months after. Differences were observed between urban and rural area for numbers reported above. Conclusion/Implications These data suggest high ED utilization by cancer patients, and variation in utilization by cancer type. Identifying the timing and risk factors of ED visit for each cancer type, especially on frequent ED users presents opportunities to improve care in oncology clinics and ED

On-unit CT measures as tools for artificial intelligence to identify random vs. systematic anatomical changes in radiotherapy patients

Background: Although head and neck (H&N) cancer survival is steadily increasing, the close proximity of tumor volumes to organs at risk (OARs) makes radiotherapy planning and delivery challenging for these patients. Changes in patient anatomy (i.e. weight-loss, tumor shrinkage) over 7 weeks of daily radiotherapy may result in increased dosages of radiation to OARs relative to the original treatment plan, consequently hindering post-treatment quality of life. Artificial intelligence-based approaches can improve prediction and monitoring of these effects through identification of systematic changes. Objective: To collect and perform an analysis of on-unit CT measurements as surrogate measures of dose changes. Correlations among CT measures may indicate random vs. systematic changes in dose deposition (i.e. dosimetry) and further improve artificial intelligence-based approaches that determine which patients benefit most from treatment re-planning. Methods: 250 H&N cancer patients treated with curative chemo-radiotherapy were retrospectively analyzed. Five CT measures including face and neck diameter, chin and shoulder position, and head shift were calculated motivated by current literature. Dosimetric changes were calculated for OARs (pharyngeal constrictor, brainstem, parotid and submandibular glands) and tumour volumes. Conventional correlation analysis and hierarchical clustering were performed to assess group-wise correlations. K-medoid clustering and principal components analysis were conducted to infer groupings of the patients as random or systematic. Results: There is a positive correlation between increased dosages to central-axis anatomical structures (spinal cord, pharyngeal constrictor, submandibular glands) and systematic weight-loss effects (change in BMI and weight loss through the face and neck). In line with current literature, clustering indicated that 30.4% of the cohort exhibited systematic anatomical changes, potentially correctable by re-planning. MANOVA confirmed that the systematic anatomical changes corresponded to the spinal cord and brain stem (p<0.005), and Mann-Whitney U tests confirmed that the measures could identify systematic dose increases to the pharyngeal constrictor (p<0.05). Further statistical analyses will be conducted. Conclusions: On-unit CT measures appear to be able to distinguish random and systematic dosimetric effects, correlated with changes in dose as expected. These measures can be utilized to improve artificial intelligence-based patient monitoring and intervention techniques

Dose-Escalated Stereotactic Body Radiation Therapy for Prostate Cancer: Quality of Life Comparison of Two Prospective Trials

IntroductionThe optimal prostate stereotactic body radiation therapy (SBRT) dose-fractionation scheme is controversial. This study compares long-term quality of life (QOL) from two prospective trials of prostate SBRT to investigate the effect of increasing dose (NCT01578902 and NCT01146340).Material and MethodsPatients with localized prostate cancer received SBRT 35 or 40 Gy delivered in 5 fractions, once per week. QOL was measured using the Expanded Prostate Cancer Index Composite (EPIC) at baseline and every 6 months. Fisher’s exact test and generalized estimating equations were used to analyze proportions of patients with clinically significant change and longitudinal changes in QOL.Results114 patients were included, 84 treated to 35 Gy and 30 treated to 40 Gy. Median QOL follow-up was 56 months (interquartile range [IQR] 46-60) and 38 months (IQR 32-42), respectively. The proportion of patients reporting clinically significant declines in average urinary, bowel, and sexual scores were not significantly different between dose levels, and were 20.5 vs. 24.1% (p=0.60), 26.8 vs. 41.4% (p=0.16), and 42.9 vs. 38.5% (p=0.82), respectively. Similarly, longitudinal analysis did not identify significant differences in QOL between treatment groups.ConclusionDose-escalated prostate SBRT from 35 to 40 Gy in 5 fractions was not associated with significant decline in long-term QOL

Dynamics of three-dimensional telomere profiles of circulating tumor cells in patients with high-risk prostate cancer who are undergoing androgen deprivation and radiation therapies

Introduction: Accurate assessment and monitoring of the therapeutic efficacy of locally advanced prostate cancer remains a major clinical challenge. Contrary to prostate biopsies, circulating tumor cells (CTCs) are a cellular source repeatedly obtainable by blood sampling and could serve as a surrogate marker for treatment efficacy. In this study, we used size-based filtration to isolate and enumerate CTCs from the blood of 20 patients with high-risk (any one of cT3, Gleason 810, or prostate-specific antigen&gt;20 ng/ml), nonmetastatic, and treatment-naive prostate cancer before and after androgen deprivation therapy (ADT) and radiation therapy (RT). Materials and methods: We performed 3D telomere-specific quantitative fluorescence in situ hybridization on isolated CTCs to determine 3D telomere profiles for each patient before and throughout the course of both ADT and RT. Results: Based on the distinct 3D telomere signatures of CTC before treatment, patients were divided into 3 groups. ADT and RT resulted in distinct changes in 3D telomere signatures of CTCs, which were unique for each of the 3 patient groups. Conclusion: The ability of 3D telomere analysis of CTCs to identify disease heterogeneity among a clinically homogeneous group of patients, which reveals differences in therapeutic responses, provides a new opportunity for better treatment monitoring and management of patients with high-risk prostate cancer. CC BY-NC-ND 4.0</p

Predicting Erectile Dysfunction after Highly Conformal, Hypofractionated Radiotherapy to the Prostate

Background: Erectile dysfunction (ED) is common after prostate cancer treatment. It has been studied for conventional radiotherapy, but associations in the hypofractionated radiotherapy context are less clear. This study aimed to determine which factors are predicted for worsening ED after highly conformal, modestly hypofractionated radiotherapy to the prostate. Methods: Two hundred and twelve patients treated with 6000 cGy in twenty fractions across four centers were included in this study. Demographic, clinical, and dosimetry factors were then evaluated for post-treatment declines in erectile function using logistic regression and an explainable machine learning-based neural network. Results: 212 patients with a median follow-up of 3.6 years were evaluated. A total of 104 (49%) patients received androgen deprivation therapy. Prior to treatment, 52 (25%) patients were on ED medication. Mean doses to the penile bulb, penile crus, and penile shaft were 2490 (IQR: 1529–3656) cGy, 2095 (1306–3036) cGy, and 444 (313–650) cGy, respectively. Fifty-nine (28%) patients had a worsening of ED after treatment. On multivariable analysis, only the mean dose to the penile shaft [OR >345 vs. ≤345: 4.47 (1.43–13.99); p = 0.010] and pretreatment use of ED medication [OR yes vs. no: 12.5 (5.7–27.5; p < 0.001)] predicted for worsening ED. The neural network confirmed that the penile shaft mean dose and pre-treatment ED medication use are the most important factors in predicting ED. Conclusions: Pre-treatment ED and penile shaft dosimetry are important predictors for ED after hypofractionated radiotherapy for prostate cancer